LinkedIn facebook twitter youtube
News archive

MPE is very proud to have been accepted as member of the Patients’ and Consumers’ Working Party (PCWP) at the European Medicines Agency for the term 2016-2019.

The PCWP provides a platform for exchange of information and discussion of issues of common interest between the EMA and patients and consumers. It was established in 2006, and has enabled the Agency to build upon its existing interactions with patients and consumers. It provides recommendations to the EMA and its human scientific committees on all matters of interest in relation to medicines.

MPE and its members have been working intensively over the last couple of years to move from anecdotal reporting to evidence based advocacy. The most recent example is the development of the European Atlas of Access to Myeloma Treatment, which is about to be launched. We will continue to develop solid evidence on the needs and wants of myeloma patients across Europe, and work hard to ensure these are taken into account by the regulator.

You can find more information on the PCWP here http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000708.jsp&mid=WC0b01ac0580028d32

Recent news

» Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

» Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy